logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
T

Thomas Burke

universite de montpellier

41H指数
168论文数
5.8K被引数
收录论文 38
发表时间
logo
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France接受≥17个周期帕博利珠单抗单药治疗作为一线疗法及用于既往治疗过的晚期NSCLC患者的真实世界结局：法国多中心观察性研究
errRespiratory Medicine and Research
IF1.8
err2025-12-01
err0
PREAI
errPerol, Maurice; Audigier-Valette, Clarisse; Lena, Herve; Massiani, Marie-Ange; Quantin, Xavier; Santorelli, Melissa; Apert, Marion; Spampinato, Axelle; Burke, Thomas; Chouaid, Christos
err分享
err收藏
Real-World treatment outcomes for advanced NSCLC in Greece
errEUROPEAN RESPIRATORY JOURNAL
IF21
err2023-10-27
err0
PREAI
errKokkotou, Eleni; Stournara, Lamprini; Mani, Maria; Gkiozos, Ioannis; Tsagouli, Sofia; Syrigos, Nikolaos; Burke, Thomas; Desiniotis, Andreas; Dimitriadis, Ioannis; Charpidou, Andriani
err分享
err收藏
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
errFRONTIERS IN ONCOLOGY
IF3.3
err2022-10-17
err14
errOAAI
errLiu, Stephen V.; Hu, Xiaohan; Li, Yeran; Zhao, Bin; Burke, Thomas; Velcheti, Vamsidhar
err分享
err收藏
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
errJTO CLINICAL AND RESEARCH REPORTS
IF3.5
err2022-09-01
err8
errOAAI
errGoto, Yasushi; Tamura, Atsuhisa; Matsumoto, Hirotaka; Isobe, Kazutoshi; Ozaki, Tomohiro; Santorelli, Melissa L.; Taniguchi, Kazuko; Kamitani, Tetsu; Irisawa, Masato; Kanda, Kingo; Abe, Machiko; Burke, Thomas; Nokihara, Hiroshi
err分享
err收藏
Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Measurement Properties and Estimated Clinically Meaningful Thresholds From a Phase 3 Study
errJTO CLINICAL AND RESEARCH REPORTS
IF3.5
err2022-04-01
err4
errOAAI
errWilliams, Paul; Burke, Thomas; Norquist, Josephine M.; Daskalopoulou, Christina; Speck, Rebecca M.; Samkari, Ayman; Eremenco, Sonya; Coons, Stephen Joel
err分享
err收藏
Disease-free survival (DFS) as a predictor of overall survival (OS) in completely resected early stage non-small cell lung cancer (NSCLC)
errANNALS OF ONCOLOGY
IF65.4
err2022-04-01
err1
errOAAI
errWest, H.; Hu, X.; Burke, T.; Walker, M. S.; Wang, Y.; Samkari, A.
err分享
err收藏
Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection
errANNALS OF ONCOLOGY
IF65.4
err2022-04-01
err0
errOAAI
errWest, H.; Hu, X.; Burke, T.; Walker, M. S.; Wang, Y.; Samkari, A.
err分享
err收藏
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
errFRONTIERS IN ONCOLOGY
IF3.3
err2022-03-25
err24
errOAAI
errVelcheti, Vamsidhar; Hu, Xiaohan; Yang, Lingfeng; Pietanza, M. Catherine; Burke, Thomas
err分享
err收藏
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab
errJCO CLINICAL CANCER INFORMATICS
IF2.8
err2021-12-01
err3
PREAI
errJemielita, Thomas; Li, Xiaoyun (Nicole); Burke, Thomas; Liaw, Kai-Li; Zhou, Wei; Chen, Cong
err分享
err收藏
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data
errJCO CLINICAL CANCER INFORMATICS
IF2.8
err2021-12-01
err12
PREAI
errJemielita, Thomas; Li, Xiaoyun (Nicole); Piperdi, Bilal; Zhou, Wei; Burke, Thomas; Chen, Cong
err分享
err收藏
Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan
errANNALS OF ONCOLOGY
IF65.4
err2021-09-01
err0
errOAAI
errNokihara, H.; Santorelli, M. L.; Taniguchi, K.; Kamitani, T.; Irisawa, M.; Kanda, K.; Abe, M.; Burke, T.; Goto, Y.
err分享
err收藏
Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
errANNALS OF ONCOLOGY
IF65.4
err2021-09-01
err0
errOAAI
errGoto, Y.; Santorelli, M. L.; Taniguchi, K.; Kamitani, T.; Irisawa, M.; Kanda, K.; Abe, M.; Burke, T.; Nokihara, H.
err分享
err收藏
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
errSCIENTIFIC REPORTS
IF3.9
err2021-04-28
err49
errOAAI
errVelcheti, Vamsidhar; Hu, Xiaohan; Piperdi, Bilal; Burke, Thomas
err分享
err收藏
Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices
errANNALS OF ONCOLOGY
IF65.4
err2020-09-01
err4
errOAAI
errVelcheti, V.; Hu, X.; Chen, X.; Piperdi, B.; Burke, T.
err分享
err收藏
Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall SurvivalPembrolizumab用于先前治疗的PD-L1-expressing晚期NSCLC: 真实世界的治疗时间和总生存期
errCLINICAL LUNG CANCER
IF3.3
err2020-09-01
err9
errOAAI
errVelcheti, Vamsidhar; Chandwani, Sheenu; Chen, Xin; Piperdi, Bilal; Burke, Thomas
err分享
err收藏
THE IMPACT OF RHEUMATOID ARTHRITIS (RA) ON A PATIENT'S ABILITY TO WORK AND EARLY RETIREMENT DUE TO RA
errVALUE IN HEALTH
IF6
err2018-10-01
err0
errOAAI
errWalid, F.; Capron, J.; De Leonardis, F.; Dilla, T.; Diaz Cerezo, S.; Inciarte-Mundo, J.; Burke, T.
err分享
err收藏
PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC - A NETWORK META-ANALYSIS
errVALUE IN HEALTH
IF6
err2018-10-01
err0
errOAAI
errFrederickson, A. M.; Arndorfer, S.; Lorenzi, M.; Insinga, R.; Chandwani, S.; Burke, T.
err分享
err收藏
UTILIZATION AND TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PREDICTIVE MOLECULAR BIOMARKER (BMX) TESTS
errVALUE IN HEALTH
IF6
err2017-10-01
err0
errOAAI
errKothari, S.; Arunachalam, A.; Tsao, M.; Lee, D. H.; Kambartel, K.; Isobe, H.; Huang, M.; Escosteguy Barrios, C. H.; Khattak, A.; de Marinis, F.; Cao, X.; Burke, T.; Lopez, M. A.; De Castro, J.
err分享
err收藏
COST-EFFECTIVENESS OF PEMBROLIZUMAB VS. DO CETAXEL FOR TREATMENT OF PREVIOUSLY TREATED PD-L1 POSITIVE ADVANCED NSCLC PATIENTS
errVALUE IN HEALTH
IF6
err2016-11-01
err1
PREAI
errHuang, M.; Lou, Y.; Pellissier, J.; Burke, T.; Liu, F. X.; Xu, R.; Velcheti, V.
err分享
err收藏
Clarification on Tartari et al.: Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients
errCANCER TREATMENT REVIEWS
IF10.5
err2016-11-01
err3
PREAI
errBurke, Thomas
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
J
Jean‐Yves Blay
H 指数: 158 · 论文数: 2.4K
M
Ming‐Sound Tsao
H 指数: 151 · 论文数: 1.6K
J
Jaap Verweij
H 指数: 115 · 论文数: 1.1K
M
Matti Aapro
H 指数: 103 · 论文数: 865
I
Ian Judson
H 指数: 101 · 论文数: 588
查看更多